The authors of this Review wish to issue the following correction: Table 3 in our recent paper contained incorrect details regarding the administration of paromomycin. In this table, administration of paromomycin is indicated to be oral (PO), however, as described in the literature, this antibiotic has been employed for canine leishmaniosis therapy exclusively by the subcutaneous (SC) route. In addition, it is well known that all aminoglycoside drugs have a limited intestinal absorption, with no efficacy on systemic diseases when employed PO.
Bibliographical notePublisher Copyright:
© 2017 Elsevier Ltd